Table 2.
Comparison of adverse events of interest in the PACCE and CAIRO2 studies.
| PACCE oxaliplatin cohort [43] | CAIRO2 [47] | |||||
|---|---|---|---|---|---|---|
| (N = 823) | (N = 755) | |||||
| Ox + Bev + Pmab | Ox + Bev | Cap, Ox + Bev + Cmab | Cap, Ox + Bev | |||
| Grade 3 | Grade 4 | Grade 3 | Grade 4 | Grade 3/4 | Grade 3/4 | |
| Incidence of toxicity, % | ||||||
|
| ||||||
| Skin toxicity | 35 | 1 | 1 | 0 | 39.1 | 20.8 |
| Diarrhea | 22 | 2 | 12 | 1 | 26.0 | 19.1 |
| Infection | 16 | 2 | 8 | 2 | 6.0 | 6.8 |
| Hypertension | 4 | 0 | 5 | 0 | 9.3 | 14.8 |
| Hypomagnesemia | 3 | 1 | 0 | 0 | NR | NR |
| Neuropathy* | 3 | <1 | 7 | 0 | 7.7 | 10.4 |
| Nausea/vomiting† | 13 | 0 | 6 | 1 | 6.3/6.0* | 8.5/8.2* |
| Deep vein thrombosis | 7 | 0 | 8 | 0 | NR | NR |
| Pulmonary embolism | 0 | 6 | 0 | 4 | NR | NR |
| Venous thromboembolic events | NR | NR | NR | NR | 8.2 | 6.8 |
| Arterial thromboembolic events | NR | NR | NR | NR | 2.2 | 3.3 |
Bev: bevacizumab; Cap: capecitabine; Cmab: cetuximab; NR: not reported; Ox: oxaliplatin; PACCE: Panitumumab Advanced Colorectal Cancer Evaluation; Pmab: panitumumab.
*Neuropathy events were reported as “sensory neuropathy” in CAIRO2.
†The incidence of nausea and vomiting was reported together in PACCE but as separate adverse events in CAIRO2. The first number indicates the reported incidence of nausea and the second number indicates the incidence of vomiting.